Parsippany’s Pacira Pharmaceuticals Inc. has announced two new leaders.
Dr. Scott Braunstein will oversee the company’s commercial and medical affairs as chief operating officer, while continuing to manage strategy and corporate development.
As chief scientific officer, Dr. Richard Scranton will direct the company’s clinical research while continuing to lead scientific communications, market access and health outcomes research and analytics for EXPAREL, the company’s non-opioid option for managing postsurgical pain.
“Scott and Rich have made significant contributions to Pacira, and we’re very pleased to announce these expanded roles for each of them,” said Chairman and CEO Dave Stack. “Scott is an outstanding and committed leader who has played a critical role in defining and executing our growth strategy for EXPAREL, including our broad commercial collaboration with Johnson & Johnson. Scott’s integral involvement in all aspects of this partnership makes him the ideal executive to lead our commercial initiatives.
“Rich has an exceptional track record of delivering results, and I have every confidence he will ensure operational excellence across all aspects of our clinical research programs for EXPAREL.”
In addition to the clinical research programs, Scranton oversees the company’s health outcomes and value assessment programs, academic research collaborations, scientific communications and market access strategies.
Braunstein currently leads the company’s strategy and corporate development activities, including spearheading the company’s flagship strategic collaboration with Johnson & Johnson for EXPAREL in the orthopedic surgical setting. He has more than 20 years of experience both as a practicing physician and investor, as well as expertise from numerous commercial, consulting and operational roles within biotechnology and pharmaceutical companies.
